MECHANISM OF RETINAL DAMAGE IN AUTOIMMUNE RETINOPATHY

自身免疫性视网膜病视网膜损伤的机制

基本信息

  • 批准号:
    7715961
  • 负责人:
  • 金额:
    $ 2.77万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-05-01 至 2009-04-30
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Cancer Associated Retinopathy (CAR) is a paraneoplastic disease in which retinal degeneration occurs as a result of the patient's immune response to cancer in a distal part of the body. Treatment for the primary malignancy does not alter the course of visual loss and there is neither a means of cure nor prevention of such retinal degenerations. Autoantibodies against retinal proteins are present in serum of CAR patients but whether these antibodies themselves induce retinal degeneration is a source of debate. Retinal dysfunction or degeneration is assessed by recording the electroretinogram (ERG). The ERG is a recording of the change in voltage across the retina in response to light and is recorded from an electrode placed against the cornea. The aim of the proposed studies was to use the ERG to assess changes in retinal function in rats following intravitreal injection autoantibodies isolated from CAR patients. The overall aim of the research is to determine the molecular mechanisms altered by autoantibodies against retinal proteins that lead to retinal degeneration. Understanding the molecular mechanisms that result in retinal degeneration in these patients is the first step towards the developing and testing of preventative treatments.
这个子项目是众多研究子项目之一

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Brett G Jeffrey其他文献

Brett G Jeffrey的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Brett G Jeffrey', 18)}}的其他基金

TRP CHANNEL EXPRESSION AND FUNCTION IN ON-BIPOLAR CELLS
双极细胞中 TRP 通道的表达和功能
  • 批准号:
    8357814
  • 财政年份:
    2011
  • 资助金额:
    $ 2.77万
  • 项目类别:
MOLECULAR MECHANISMS OF SIGNAL TRANSDUCTION IN RETINA
视网膜信号转导的分子机制
  • 批准号:
    8357762
  • 财政年份:
    2011
  • 资助金额:
    $ 2.77万
  • 项目类别:
SIGNALING MECHANISMS OF RETINAL BIPOLAR CELLS
视网膜双极细胞的信号传导机制
  • 批准号:
    8357813
  • 财政年份:
    2011
  • 资助金额:
    $ 2.77万
  • 项目类别:
TRP CHANNEL EXPRESSION AND FUNCTION IN ON-BIPOLAR CELLS
双极细胞中 TRP 通道的表达和功能
  • 批准号:
    8173306
  • 财政年份:
    2010
  • 资助金额:
    $ 2.77万
  • 项目类别:
MOLECULAR MECHANISMS OF SIGNAL TRANSDUCTION IN RETINA
视网膜信号转导的分子机制
  • 批准号:
    8173222
  • 财政年份:
    2010
  • 资助金额:
    $ 2.77万
  • 项目类别:
MECHANISM OF RETINAL DAMAGE IN AUTOIMMUNE RETINOPATHY
自身免疫性视网膜病视网膜损伤的机制
  • 批准号:
    8173221
  • 财政年份:
    2010
  • 资助金额:
    $ 2.77万
  • 项目类别:
SIGNALING MECHANISMS OF RETINAL BIPOLAR CELLS
视网膜双极细胞的信号传导机制
  • 批准号:
    8173305
  • 财政年份:
    2010
  • 资助金额:
    $ 2.77万
  • 项目类别:
MECHANISM OF RETINAL DAMAGE IN AUTOIMMUNE RETINOPATHY
自身免疫性视网膜病视网膜损伤的机制
  • 批准号:
    7958469
  • 财政年份:
    2009
  • 资助金额:
    $ 2.77万
  • 项目类别:
MOLECULAR MECHANISMS OF SIGNAL TRANSDUCTION IN RETINA
视网膜信号转导的分子机制
  • 批准号:
    7958470
  • 财政年份:
    2009
  • 资助金额:
    $ 2.77万
  • 项目类别:
MOLECULAR MECHANISMS OF SIGNAL TRANSDUCTION IN RETINA
视网膜信号转导的分子机制
  • 批准号:
    7715962
  • 财政年份:
    2008
  • 资助金额:
    $ 2.77万
  • 项目类别:

相似海外基金

Defining the cellular origin of pathogenic autoantibodies
定义致病性自身抗体的细胞起源
  • 批准号:
    EP/Y031091/1
  • 财政年份:
    2024
  • 资助金额:
    $ 2.77万
  • 项目类别:
    Fellowship
Do autoantibodies to aberrantly glycosylated MUC1 drive extra-articular rheumatoid arthritis, and can GSK assets prevent driver antigen formation?
针对异常糖基化 MUC1 的自身抗体是否会导致关节外类风湿性关节炎,GSK 资产能否阻止驱动抗原形成?
  • 批准号:
    MR/Y022947/1
  • 财政年份:
    2024
  • 资助金额:
    $ 2.77万
  • 项目类别:
    Research Grant
Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
  • 批准号:
    479128
  • 财政年份:
    2023
  • 资助金额:
    $ 2.77万
  • 项目类别:
    Operating Grants
Autoantibodies to tumor-derived neoepitopes as biomarkers and immunoPET agents for the early detection of small cell lung cancer
肿瘤衍生新表位的自身抗体作为生物标志物和免疫 PET 试剂用于小细胞肺癌的早期检测
  • 批准号:
    10715807
  • 财政年份:
    2023
  • 资助金额:
    $ 2.77万
  • 项目类别:
Role of pharmacological activity of autoantibodies in ME/CFS
自身抗体药理活性在 ME/CFS 中的作用
  • 批准号:
    MR/Y003667/1
  • 财政年份:
    2023
  • 资助金额:
    $ 2.77万
  • 项目类别:
    Research Grant
Pathological Mechanisms of Immune-Mediated Cerebellar Ataxia with Associated Sez6L2 Autoantibodies
免疫介导的小脑共济失调与相关 Sez6L2 自身抗体的病理机制
  • 批准号:
    10740682
  • 财政年份:
    2023
  • 资助金额:
    $ 2.77万
  • 项目类别:
Sjogren's Syndrome Pathogenic Autoantibodies
干燥综合征致病性自身抗体
  • 批准号:
    10854472
  • 财政年份:
    2023
  • 资助金额:
    $ 2.77万
  • 项目类别:
Pathogenesis of idiopathic nephrotic syndrome: defining the role of B cells and autoantibodies reactive to podocyte proteins
特发性肾病综合征的发病机制:定义 B 细胞和足细胞蛋白反应性自身抗体的作用
  • 批准号:
    487849
  • 财政年份:
    2023
  • 资助金额:
    $ 2.77万
  • 项目类别:
    Operating Grants
Depleting autoantibodies for the treatment of autoimmunity
消耗自身抗体来治疗自身免疫
  • 批准号:
    10481071
  • 财政年份:
    2022
  • 资助金额:
    $ 2.77万
  • 项目类别:
Pathological Mechanisms of Immune-Mediated Cerebellar Ataxia with Associated Sez6L2 Autoantibodies
免疫介导的小脑共济失调与相关 Sez6L2 自身抗体的病理机制
  • 批准号:
    10526475
  • 财政年份:
    2022
  • 资助金额:
    $ 2.77万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了